Stable knockdown of LPA1 expression (using small-hairpin RNAs or treatments with the LPA1–3 antagonist Ki16425) inhibited the progression of osteolytic bone metastases by impairing breast cancer cell proliferation, motility and cytokine secretions [8]. Here, LPAR1 is linked to breast cancer.